Neal Shore, MD
Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Genesis CareDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Cold GenesysDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:UrogenDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:PhosphorusDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Pacific EdgeDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Exact SciencesDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Sesen BioDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Sanofi GenzymeDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:PropellaDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:NymoxDate added:Date updated:04/10/2024